Sara E Espinoza1,2,3, Nicolas Musi2,3,4, Chen-Pin Wang2,3,5, Joel Michalek5, Beverly Orsak2,3,4, Terry Romo2,3, Becky Powers1,3, Alice Conde2,3, Melody Moris2,3, Darcy Bair-Kelps2,3, Yan Li2,3, Vinutha Ganapathy2,3, Tyson E Jergensen2,3, Lauri C Kelly2,3, Rozmin Jiwani3,6. 1. Division of Geriatrics, Gerontology, and Palliative Medicine, Department of Medicine, University of Texas Health Science Center at San Antonio, Texas. 2. Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, Texas. 3. Geriatric Research, Education, and Clinical Center, South Texas Veterans Health Care System, San Antonio, Texas. 4. Division of Diabetes, Department of Medicine, Texas. 5. Department of Epidemiology and Biostatistics, Texas. 6. School of Nursing, University of Texas Health Science Center at San Antonio, Texas.
Abstract
BACKGROUND: Frailty is a geriatric syndrome that leads to poor health outcomes with aging. Previous studies have demonstrated that insulin resistance and inflammation predict frailty onset. Metformin is a widely used, well-tolerated drug that improves insulin sensitivity and displays anti-inflammatory properties. It is also known to prevent diabetes onset in adults with prediabetes. We hypothesize that metformin in older adults with prediabetes will promote healthy aging and prevent frailty. Here we describe an ongoing placebo-controlled, double-blinded clinical trial of metformin for the prevention of frailty in older adults with prediabetes. METHODS:Older adults aged more than 65 years are randomized to metformin or placebo and are followed for 2 years. Prediabetes, required for inclusion, is assessed by 2-hour oral glucose tolerance test. Exclusion criteria are baseline frailty (Fried criteria), diabetes, dementia, untreated depression, active malignancy, or severe cardiovascular, pulmonary, and neurologic diseases. Primary outcome is frailty; secondary outcomes are physical function (Short Physical Performance Battery), systemic and skeletal muscle tissue inflammation, muscle insulin signaling, insulin sensitivity (insulin clamp), glucose tolerance (oral glucose tolerance test), and body composition (dual-energy x-ray absorptiometry). Subjects are followed every 3 months for safety assessments and every 6 months for frailty assessment (Fried criteria) and oral glucose tolerance test, and every 12 or 24 months for secondary outcomes. Enrollment of 120 subjects (completers) will take place over a 2-year period. CONCLUSION:Metformin is being examined in this study as a potential therapeutic agent to prevent frailty in older adults with prediabetes. Findings from this trial may have future implications for the screening and potential treatment of prediabetes in older patients withmetformin for the prevention of frailty. Published by Oxford University Press on behalf of The Gerontological Society of America 2019.
RCT Entities:
BACKGROUND: Frailty is a geriatric syndrome that leads to poor health outcomes with aging. Previous studies have demonstrated that insulin resistance and inflammation predict frailty onset. Metformin is a widely used, well-tolerated drug that improves insulin sensitivity and displays anti-inflammatory properties. It is also known to prevent diabetes onset in adults with prediabetes. We hypothesize that metformin in older adults with prediabetes will promote healthy aging and prevent frailty. Here we describe an ongoing placebo-controlled, double-blinded clinical trial of metformin for the prevention of frailty in older adults with prediabetes. METHODS: Older adults aged more than 65 years are randomized to metformin or placebo and are followed for 2 years. Prediabetes, required for inclusion, is assessed by 2-hour oral glucose tolerance test. Exclusion criteria are baseline frailty (Fried criteria), diabetes, dementia, untreated depression, active malignancy, or severe cardiovascular, pulmonary, and neurologic diseases. Primary outcome is frailty; secondary outcomes are physical function (Short Physical Performance Battery), systemic and skeletal muscle tissue inflammation, muscle insulin signaling, insulin sensitivity (insulin clamp), glucose tolerance (oral glucose tolerance test), and body composition (dual-energy x-ray absorptiometry). Subjects are followed every 3 months for safety assessments and every 6 months for frailty assessment (Fried criteria) and oral glucose tolerance test, and every 12 or 24 months for secondary outcomes. Enrollment of 120 subjects (completers) will take place over a 2-year period. CONCLUSION:Metformin is being examined in this study as a potential therapeutic agent to prevent frailty in older adults with prediabetes. Findings from this trial may have future implications for the screening and potential treatment of prediabetes in older patients with metformin for the prevention of frailty. Published by Oxford University Press on behalf of The Gerontological Society of America 2019.
Authors: Karen Bandeen-Roche; Christopher L Seplaki; Jin Huang; Brian Buta; Rita R Kalyani; Ravi Varadhan; Qian-Li Xue; Jeremy D Walston; Judith D Kasper Journal: J Gerontol A Biol Sci Med Sci Date: 2015-08-21 Impact factor: 6.053
Authors: Joshua I Barzilay; Caroline Blaum; Tisha Moore; Qian Li Xue; Calvin H Hirsch; Jeremy D Walston; Linda P Fried Journal: Arch Intern Med Date: 2007-04-09
Authors: Alejandro Martin-Montalvo; Evi M Mercken; Sarah J Mitchell; Hector H Palacios; Patricia L Mote; Morten Scheibye-Knudsen; Ana P Gomes; Theresa M Ward; Robin K Minor; Marie-José Blouin; Matthias Schwab; Michael Pollak; Yongqing Zhang; Yinbing Yu; Kevin G Becker; Vilhelm A Bohr; Donald K Ingram; David A Sinclair; Norman S Wolf; Stephen R Spindler; Michel Bernier; Rafael de Cabo Journal: Nat Commun Date: 2013 Impact factor: 14.919
Authors: M Sue Kirkman; Vanessa Jones Briscoe; Nathaniel Clark; Hermes Florez; Linda B Haas; Jeffrey B Halter; Elbert S Huang; Mary T Korytkowski; Medha N Munshi; Peggy Soule Odegard; Richard E Pratley; Carrie S Swift Journal: Diabetes Care Date: 2012-10-25 Impact factor: 19.112
Authors: Joshua I Barzilay; George A Cotsonis; Jeremy Walston; Ann V Schwartz; Suzanne Satterfield; Iva Miljkovic; Tamara B Harris Journal: Diabetes Care Date: 2009-01-26 Impact factor: 19.112
Authors: Jens-Oliver Bock; Hans-Helmut König; Hermann Brenner; Walter E Haefeli; Renate Quinzler; Herbert Matschinger; Kai-Uwe Saum; Ben Schöttker; Dirk Heider Journal: BMC Health Serv Res Date: 2016-04-14 Impact factor: 2.655
Authors: Tina E Brinkley; Jamie N Justice; Shubhashrita Basu; Scott R Bauer; Kah Poh Loh; Peter Mukli; Ted Kheng Siang Ng; Indira C Turney; Luigi Ferrucci; Steven R Cummings; Stephen B Kritchevsky Journal: Geroscience Date: 2022-10-15 Impact factor: 7.581
Authors: Ivan Aprahamian; Marcus K Borges; Denise J C Hanssen; Hans W Jeuring; Richard C Oude Voshaar Journal: Clin Interv Aging Date: 2022-06-22 Impact factor: 3.829
Authors: Helen P Hazuda; Qing Pan; Hermes Florez; José A Luchsinger; Jill P Crandall; Elizabeth M Venditti; Sherita H Golden; Andrea M Kriska; George A Bray Journal: J Gerontol A Biol Sci Med Sci Date: 2021-04-30 Impact factor: 6.053
Authors: Naila Ijaz; Brian Buta; Qian-Li Xue; Denise T Mohess; Archana Bushan; Henry Tran; Wayne Batchelor; Christopher R deFilippi; Jeremy D Walston; Karen Bandeen-Roche; Daniel E Forman; Jon R Resar; Christopher M O'Connor; Gary Gerstenblith; Abdulla A Damluji Journal: J Am Coll Cardiol Date: 2022-02-08 Impact factor: 24.094
Authors: Anne B Newman; Stephen B Kritchevsky; Jack M Guralnik; Steven R Cummings; Marcel Salive; George A Kuchel; Jennifer Schrack; Martha Clare Morris; David Weir; Andrea Baccarelli; Joanne M Murabito; Yoav Ben-Shlomo; Mark A Espeland; James Kirkland; David Melzer; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2020-01-01 Impact factor: 6.591